Additional information
| Trade Name | Nexavar |
|---|---|
| Generic Name | Sorafenib Tosilate |
| Manufacturer | Bayer plc |
| Drug Type | Oncology |
| Indication | Liver / Renal Cancer |
| Doasage Form | Tablet |
| Packaging | 60 Tablets |
NEXAVAR (Sorafenib Tosylate)-200 mg
NEXAVAR (Sorafenib Tosylate) is classified as a, tyrosine kinase inhibitor, angiogenesis inhibitor, VEGF inhibitor.
It is indicated for the treatment of
- type of liver cancer called hepatocellular carcinoma (HCC) that cannot be removed by surgery
- type of advanced kidney cancer called renal cell carcinoma (RCC)
- type of progressive, locally advanced, or metastatic thyroid cancer called differentiated thyroid carcinoma (DTC) that can no longer be treated with radioactive iodine and is progressing also known as papillary/follicular/Hürthle cell thyroid carcinoma.
